Stryker Co. (NYSE:SYK) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Stryker Co. (NYSE:SYKGet Free Report) have received an average rating of “Moderate Buy” from the fifteen research firms that are covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $331.52.

A number of research firms have recently weighed in on SYK. Wells Fargo & Company increased their target price on shares of Stryker from $336.00 to $364.00 and gave the stock an “overweight” rating in a report on Wednesday, January 31st. Roth Mkm increased their target price on shares of Stryker from $345.00 to $348.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. Citigroup increased their price target on shares of Stryker from $340.00 to $362.00 and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Truist Financial increased their price target on shares of Stryker from $330.00 to $345.00 and gave the stock a “hold” rating in a research note on Wednesday, January 31st. Finally, Morgan Stanley increased their price target on shares of Stryker from $300.00 to $320.00 and gave the stock an “equal weight” rating in a research note on Monday, December 4th.

Check Out Our Latest Analysis on SYK

Stryker Stock Performance

NYSE SYK opened at $341.03 on Thursday. The company has a 50-day simple moving average of $308.59 and a two-hundred day simple moving average of $289.80. The company has a quick ratio of 0.97, a current ratio of 1.58 and a debt-to-equity ratio of 0.59. Stryker has a 12-month low of $249.98 and a 12-month high of $346.59. The firm has a market cap of $129.57 billion, a price-to-earnings ratio of 41.34, a PEG ratio of 2.78 and a beta of 0.90.

Stryker (NYSE:SYKGet Free Report) last posted its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.27 by $0.19. The business had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The company’s revenue was up 11.8% on a year-over-year basis. During the same period in the prior year, the business posted $3.00 earnings per share. On average, equities analysts forecast that Stryker will post 11.87 EPS for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be paid a dividend of $0.80 per share. The ex-dividend date is Wednesday, March 27th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.94%. Stryker’s dividend payout ratio is presently 38.79%.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 201,146 shares of the business’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $342.90, for a total value of $68,972,963.40. Following the completion of the sale, the director now directly owns 3,755,128 shares of the company’s stock, valued at approximately $1,287,633,391.20. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Stryker news, Director Allan C. Golston sold 3,273 shares of the business’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $341.00, for a total value of $1,116,093.00. Following the completion of the sale, the director now directly owns 14,242 shares of the company’s stock, valued at approximately $4,856,522. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Ronda E. Stryker sold 201,146 shares of the business’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the completion of the sale, the director now directly owns 3,755,128 shares of the company’s stock, valued at $1,287,633,391.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 261,975 shares of company stock valued at $86,664,513. Company insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On Stryker

Several large investors have recently added to or reduced their stakes in SYK. Bremer Bank National Association raised its position in Stryker by 4.0% in the 4th quarter. Bremer Bank National Association now owns 888 shares of the medical technology company’s stock valued at $266,000 after buying an additional 34 shares during the last quarter. Simon Quick Advisors LLC lifted its position in shares of Stryker by 3.0% during the 4th quarter. Simon Quick Advisors LLC now owns 1,158 shares of the medical technology company’s stock valued at $347,000 after acquiring an additional 34 shares during the period. Consolidated Portfolio Review Corp lifted its position in shares of Stryker by 3.6% during the 4th quarter. Consolidated Portfolio Review Corp now owns 983 shares of the medical technology company’s stock valued at $294,000 after acquiring an additional 34 shares during the period. FourThought Financial Partners LLC lifted its position in shares of Stryker by 3.3% during the 4th quarter. FourThought Financial Partners LLC now owns 1,076 shares of the medical technology company’s stock valued at $322,000 after acquiring an additional 34 shares during the period. Finally, Catalyst Financial Partners LLC lifted its position in shares of Stryker by 3.0% during the 4th quarter. Catalyst Financial Partners LLC now owns 1,154 shares of the medical technology company’s stock valued at $346,000 after acquiring an additional 34 shares during the period. 76.24% of the stock is owned by hedge funds and other institutional investors.

Stryker Company Profile

(Get Free Report

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies.

Featured Stories

Analyst Recommendations for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.